Burden of adult atopic dermatitis and unmet needs with existing therapies

Abstract

Objective

Patients with atopic dermatitis (AD) have low treatment satisfaction. In this study, we evaluated the humanistic burden, treatment satisfaction, and treatment expectations in patients with AD in the United States.

Methods

Adults with AD recruited through the National Eczema Association and clinical sites completed a web-based survey comprising the Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD), Dermatology Life Quality Index; Work Productivity and Activity Impairment Questionnaire-Atopic Dermatitis; Treatment Satisfaction Questionnaire for Medication (TSQM); and answered questions on healthcare provider (HCP) visits, treatment history, and treatment goals. Descriptive analyses were performed to compare participants by severity.

Results

Among 186 participants (mean [standard deviation] age 39.7 [15.3] years, 79.6% female), 26.9%, 44.6%, and 26.3% of the participants had mild, moderate, or severe AD, respectively, based on PO-SCORAD. Greater disease severity was associated with a greater impact on work and daily life, decreased TSQM scores, and increased HCP visits. Corticosteroid topical cream or ointment (53.8%) and oral antihistamines (31.2%) were most commonly used for the treatment of AD. Participants reported declining/stopping/changing AD treatment due to the potential for side effects or lack of efficacy. ‘Leading normal lives’ (28.0%) and ‘being itch-free’ (33.9%) were important treatment goals.

Conclusions

Individuals with AD, especially severe disease, face a considerable humanistic burden even while using treatment.

Keywords:

• Atopic dermatitis
• quality of life
• work productivity
• treatment satisfaction

Acknowledgements

Leo J. Philip Tharappel and Amit Kumar Koushik of Eli Lilly Services India Private Limited, Bengaluru, India provided medical writing and editorial support. Eli Lilly and Company, United States funded support for this assistance.

Disclosure statement

EDB and JC are employed by Evidera, which provides consulting and other research services to pharmaceutical, device, government, and non-government organizations. In their salaried positions, they work with a variety of companies and organizations and are precluded from receiving any payment or honoraria directly from these organizations for services rendered. EJP, ARA, and ZD are employed by and own stock in Eli Lilly and Company. ARA has consulted for Henkel and received the Pfizer Independent Grant for Learning and Change. WSB has received grant funding from Pfizer and advisory board honoraria from Pfizer and Incyte. LB has received advisory board honoraria from Incyte. WSB and LB are salaried employees of the National Eczema Association, which has received grants and sponsorship awards from a variety of industry partners (full list at https://nationaleczema.org/about-nea/corporate-supporters).

Data availability statement

YouGov provided Evidera with de-identified, fully documented datasets. Evidera may provide the datasets generated during and/or analyzed during the current study upon request; contact Elizabeth Bacci at [email protected].

Additional information

Funding

Eli Lilly and Company provided the funding for the study and the manuscript.